Lantern Pharma Announces Successful Outcome of FDA Type C Meeting Request for HARMONIC™ Phase 2 Trial of LP-300 in Never-Smokers with NSCLC

Lantern Pharma Inc. (LTRN)

We couldn't retrieve the full text for this release. Read it on the company's site.